Unity Biotechnology Inc. (UBX)
0.99
-0.07 (-6.60%)
At close: Apr 03, 2025, 3:59 PM
1.05
6.06%
After-hours: Apr 03, 2025, 07:46 PM EDT
-6.60% (1D)
| Bid | 0.93 |
| Market Cap | 16.7M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.54 |
| PE Ratio (ttm) | -0.64 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 117,217 |
| Avg. Volume (20D) | 283,626 |
| Open | 1.03 |
| Previous Close | 1.06 |
| Day's Range | 0.98 - 1.03 |
| 52-Week Range | 0.94 - 3.10 |
| Beta | 1.02 |
About UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic dis...
Industry Biotechnology
Sector Healthcare
IPO Date May 3, 2018
Employees 16
Stock Exchange NASDAQ
Ticker Symbol UBX
Website https://unitybiotechnology.com
Analyst Forecast
According to 2 analyst ratings, the average rating for UBX stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 304.04% from the latest price.
Stock Forecasts1 week ago
-28.96%
Unity Biotechnology shares are trading lower after...
Unlock content with
Pro Subscription
2 months ago
+34.59%
Unity Biotechnology shares are trading higher after Chardan Capital initiated coverage on the stock with a Buy rating and announced a price target of $6.
